Smith Group Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Smith Group Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-160	Closed	-$4K	–	273
2021 Q4	$4K	Hold	160	–	–	﹤0.01%	346
2021 Q3	$3K	Buy	+160	New	+$3.08K	﹤0.01%	359
2020 Q3	–	Sell	-3,720	Closed	-$180K	–	307
2020 Q2	$180K	Sell	3,720 -60	-2%	-$2.88K	0.01%	168
2020 Q1	$160K	Sell	3,780 -10	-0.3%	-$412	0.01%	182
2019 Q4	$162K	Sell	3,790 -300	-7%	-$13.1K	0.01%	214
2019 Q3	$147K	Buy	4,090 +1,250	+44%	+$37.9K	0.01%	211
2019 Q2	$76K	Hold	2,840	–	–	﹤0.01%	253
2019 Q1	$76K	Sell	2,840 -8,800	-76%	-$206K	﹤0.01%	275
2018 Q4	$188K	Buy	+11,640	New	+$226K	0.01%	246
2016 Q2	–	Sell	-16,720	Closed	-$467K	–	471
2016 Q1	$467K	Sell	16,720 -150	-0.9%	-$3.27K	0.01%	172
2015 Q4	$601K	Buy	+16,870	New	+$594K	0.02%	198

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Smith Group Asset Management's ACAD Position: Q1 2022 in Review

Smith Group Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2022, closing a stake of 160 shares — an estimated $4K sold.

Smith Group Asset Management first reported a position in ACAD in Q4 2015 and held it in 11 quarters. The position peaked at $601K in Q4 2015. 263 funds tracked by Wall St. Rank hold ACAD as of Q1 2022.

Smith Group Asset Management reported no remaining Acadia Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Smith Group Asset Management sold 160 Acadia Pharmaceuticals shares in Q1 2022, an estimated $4K.
Smith Group Asset Management first reported a position in Acadia Pharmaceuticals in Q4 2015 and held it in 11 quarters.
Smith Group Asset Management's Acadia Pharmaceuticals position peaked at $601K in Q4 2015.
263 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2022.

Based on Smith Group Asset Management's 13F filing for Q1 2022, filed 5 May 2022.